



ASBEL, an ANA/BTG3 antisense transcript required for tumorigenicity of ovarian carcinoma

Satoshi Yanagida^{1,2*}, Kenzui Taniue^{1*}, Hironobu Sugimasa¹, Emiko Nasu¹, Yasuko Takeda¹, Mana Kobayashi¹, Tadashi Yamamoto³, Aikou Okamoto² & Tetsu Akiyama¹

¹Laboratory of Molecular and Genetic Information, Institute of Molecular and Cellular Biosciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo, 113-0032, Japan, ²Department of Obstetrics and Gynecology, The Jikei University school of Medicine, 3-25-8, Nishi-shinbashi, Minato-ku, Tokyo, 105-8461, Japan, ³Division of Oncology, Department of Cancer Biology, Institute of Medical Science, The University of Tokyo, 461 Shirokanedai, Tokyo, 108-8639, Japan.

Mammalian genomes encode numerous antisense non-coding RNAs, which are assumed to be involved in the regulation of the sense gene expression. However, the mechanisms of their action and involvement in the development of diseases have not been well elucidated. The ANA/BTG3 protein is an antiproliferative protein whose expression is downregulated in prostate and lung cancers. Here we show that an antisense transcript of the *ANA/BTG3* gene, termed *ASBEL*, negatively regulates the levels of ANA/BTG3 protein, but not of *ANA/BTG3* mRNA and is required for proliferation and tumorigenicity of ovarian clear cell carcinoma. We further show that knockdown of ANA/BTG3 rescues growth inhibition caused by *ASBEL* knockdown. Moreover, we demonstrate that *ASBEL* forms duplexes with *ANA/BTG3* mRNA in the nucleus and suppresses its cytoplasmic transportation. Our findings illustrate a novel function for an antisense transcript that critically promotes tumorigenesis by suppressing translation of the sense gene by inhibiting its cytoplasmic transportation.

Recent studies have revealed that most mammalian genes express antisense transcripts^{1,2}. The majority of antisense transcripts are non-coding RNAs (ncRNAs) complementary to a region of the sense mRNA. Sense-antisense transcript pairs so far reported include genes involved in various biological processes, development and diseases, suggesting critical roles of antisense transcripts in mammalian gene expression. In contrast to microRNAs, antisense transcripts have been suggested to exert their function through a variety of mechanisms. For example, duplex formation between sense and antisense RNAs in the nucleus can modulate mRNA alternative splicing, editing and transport³⁻⁵. Sense-antisense duplex formation in the cytoplasm can change sense mRNA stability and translation efficiency⁶⁻¹⁰. It has also been suggested that some antisense transcripts bind to the corresponding DNA strand and recruit DNA methyltransferases or histone-modifying enzymes, thereby modulating sense gene expression¹¹⁻¹³. However, the exact mechanisms underlying these functions remain to be further elucidated.

ANA/BTG3 is a member of the TOB/BTG family of antiproliferative genes that regulates cell cycle progression in a variety of cell types¹⁴. It has also been reported that loss of ANA/BTG3 in normal cells induces cellular senescence via the ERK-JMJD3-p16(INK4a) signaling axis¹⁵. ANA/BTG3 expression is also known to be induced by DNA damage in a p53-dependent manner and directly represses E2F1-mediated transactivation¹⁶. In addition, ANA/BTG3 interacts with the CCR4 transcription factor-associated protein Caf1¹⁷, suggesting its involvement in cytoplasmic mRNA deadenylation and turnover. Furthermore, ANA/BTG3 expression is downregulated in prostate cancer through promoter hypermethylation¹⁸. ANA/BTG3 expression is also reduced in the majority of lung adenocarcinoma¹⁹. Thus, increasing evidence suggests that ANA/BTG3 functions as a tumor suppressor.

It has been reported that the tumor suppressor functions of p53 and WT1 are regulated by their antisense transcripts^{20,21}. We therefore searched for antisense transcripts encoded in other tumor suppressor genes. We found that ANA/BTG3 encodes an antisense transcript although most of the important tumor suppressor genes, including RB, APC, BRCA1, BRCA2, NF1 and NF2, do not. Here we show that an antisense transcript of *ANA/BTG3* termed *ASBEL* is required for the regulation of ANA/BTG3 protein expression and tumorigenicity of ovarian cancer.

SUBJECT AREAS:

OVARIAN CANCER

APOPTOSIS

LONG NON-CODING RNAs

RNA TRANSPORT

Received
22 October 2012

Accepted
22 January 2013

Published
19 February 2013

Correspondence and requests for materials should be addressed to T.A. (akiyama@iam.u-tokyo.ac.jp)

* These authors contributed equally to this work.



Results

ASBEL, an antisense transcript of ANA/BTG3. Examination of the GenBank database revealed that a highly conserved gene is encoded by the DNA strand opposite the *ANA/BTG3* gene (Fig. 1a). This gene encodes a conserved ~2-kb ncRNA (termed *ASBEL* [antisense ncRNA in the *ANA/BTG3* (*three*) locus]), the 5' region of which is complementary to a portion of the 5' untranslated region (UTR) and the first exon of *ANA/BTG3* mRNA. Strand-specific RT-PCR analysis confirmed that *ASBEL* was indeed transcribed from the DNA strand opposite to the *ANA/BTG3* gene (Fig. 1a). Northern blotting analyses showed that *ASBEL* was detected (Fig. 1b). Subcellular fractionation and RT-PCR analysis revealed that *ASBEL* was present in the nucleus (Fig. 1c and Supplementary Fig. S1), consistent with the fact that *ASBEL* is a ncRNA.

ASBEL is required for the tumorigenicity of ovarian cancer. We examined *ASBEL* expression in human ovarian cancerous tissues and adjacent non-cancerous tissues (5 serous adenocarcinoma (SA), 2 endometrioid adenocarcinoma (EA), 2 clear cell adenocarcinoma (CCC), 1 mucinous adenocarcinoma (MA), 1 dysgerminoma (Dys)). The expression of *ASBEL* was higher in 8 out of 11 ovarian cancerous tissues than in the non-cancerous tissues (Fig. 2a). Thus, to clarify the importance of *ASBEL* in ovarian tumorigenesis, we knocked down *ASBEL* expression in the JHOC5 cells by infecting with a lentivirus expressing an shRNA targeting *ASBEL* (shASBEL) (Fig. 2b). MTT assays revealed that knockdown of *ASBEL* caused a

significant reduction in the growth of JHOC5, JHOC9, and OVI5E cells (Fig. 2c). CellTiter-Glo assays also revealed that knockdown of *ASBEL* using siRNA caused a significant reduction in the growth of the CCC cell lines JHOC5, JHOC9, and OVI5E and the serous adenocarcinoma cell lines OV1063 and 2008 cells (Fig. 2d). Furthermore, AnnexinV assays showed that knockdown of *ASBEL* induced apoptosis of JHOC5 cells (Fig. 2e). When JHOC5 cells stably expressing shASBEL were transplanted into nude mice, cell growth was significantly retarded compared to JHOC5 cells infected with control lentivirus (Fig. 2f and Supplementary Fig. S2). Immunohistochemical analyses of tumor xenografts demonstrated that tumor cells were arranged in solid, tubular and partially papillary patterns, which represents an important feature of human ovarian cancer (Supplementary Fig. S2). These results suggest that *ASBEL* may be required for the tumorigenicity of ovarian cancer.

ASBEL downregulates ANA/BTG3 protein expression. Since antisense transcripts have been reported to regulate the expression of their overlapping sense transcripts^{1,2}, we investigated whether knockdown of *ASBEL* could increase the expression of *ANA/BTG3* in JHOC5, JHOC9 and OVI5E cells. RT-PCR and immunoblotting analyses revealed that knockdown of *ASBEL* using siRNA (siASBEL) resulted in an increase in the levels of *ANA/BTG3* protein, but not mRNA (Fig. 3a, b). Knockdown of *ASBEL* using shASBEL also did not affect the levels of *ANA/BTG3* mRNA (Supplementary Fig. S3). By contrast, overexpression of *ASBEL* decreased the levels of *ANA/BTG* protein, but not mRNA, compared to that of *antisense ASBEL* (Fig. 3c). These results raise the possibility that the reduction in cell growth caused by *ASBEL* knockdown is due to an increase in the expression of *ANA/BTG3* protein. Thus, we examined whether knockdown of *ANA/BTG3* could restore the growth of cells transfected with siASBEL. We found that knockdown of *ANA/BTG3* using shRNA (shANA/BTG3) could partially rescue JHOC5 cells from siASBEL-mediated growth inhibition (Fig. 3d, e). Knockdown of *ANA/BTG3* did not affect *ASBEL* expression levels (Fig. 3e and Supplementary Fig. S4). Thus, *ASBEL*-mediated downregulation of *ANA/BTG3* may be critical for the proliferation of ovarian cancer.

ASBEL-ANA/BTG3 duplexes are retained in the nucleus. To clarify the mechanisms underlying *ASBEL*-mediated downregulation of *ANA/BTG3* expression, we attempted to detect *ASBEL*-*ANA/BTG3* RNA duplexes. We overexpressed *ASBEL* fused to an oligonucleotide coding for an RNA hairpin that binds bacteriophage pp7 coat protein (*pp7-ASBEL*) in JHOC5 cells and performed RNA immunoprecipitation (RIP) analysis. Lysates prepared from JHOC5 cells transfected with the *pp7-ASBEL*, *ANA/BTG3* mRNA and FLAG-tagged pp7 coat protein expression constructs were subjected to immunoprecipitation with anti-FLAG antibody. RT-PCR analysis revealed that *ANA/BTG3* mRNA was associated with the *pp7-ASBEL* immunoprecipitates (Fig. 4a, b). By contrast, *ANA/BTG3* mRNA was not co-precipitated when *pp7-antisense ASBEL* or *pp7-mutant ASBELs* (Fig. 4a, *ASBEL-Del-1* and *-4*) that lack the region complementary to *ANA/BTG3* was transfected instead of *pp7-ASBEL* (Fig. 4b, c). In addition, *pp7-mutant ASBELs* (Fig. 4a, *ASBEL-Del-2* and *-3*) that contain the region complementary to *ANA/BTG3* efficiently coprecipitated *ANA/BTG3* mRNA (Fig. 4c). These results suggest that *ASBEL* is able to hybridize and generate *ASBEL*-*ANA/BTG3* RNA duplexes.

Because only *ANA/BTG3* protein, but not its mRNA levels are regulated by *ASBEL*, we speculated that *ASBEL*-*ANA/BTG3* RNA duplexes are retained in the nucleus. Subcellular fractionation and RT-PCR analyses showed that knockdown of *ASBEL* resulted in an increase in the amount of *ANA/BTG3* mRNA and *ANA/BTG3* protein present in the cytoplasm (Fig. 4d). To directly test the possibility that *ASBEL* may influence translation, lysates from JHOC5 cells transfected with siASBEL were fractionated through sucrose




Figure 1 | *ASBEL* is transcribed from the DNA strand opposite to *ANA/BTG3*. (a) Strand-specific RT-PCR analysis of *ASBEL*. (Upper panel) Schematic representation of the genomic organization of the region containing *ASBEL* and *ANA/BTG3*. Primers for reverse transcription (RT-primer) and PCR (PCR-primer) were designed to specifically target either the sense (Fw) or antisense strand (Rev1 and Rev2) of *ASBEL*. Oligo(dT)18 was used as a positive control. “Probe” indicates the region used for Northern blot analysis. (Lower panel) RT-PCR analysis was performed using the primers indicated. Sense RT-primers generated PCR products, whereas anti-sense RT-primers did not. (b) Northern blot analysis of *ASBEL* and *GAPDH* mRNA in JHOC5 cells. (c) Subcellular localization of *ASBEL*. JHOC5 cells were subjected to subcellular fractionation and the amounts of *ASBEL* in each fraction were evaluated by RT-PCR. *GAPDH* mRNA was used as a marker specific for the cytoplasm. *U1* was used as a nuclear marker.




Figure 2 | Knockdown of *ASBEL* induces apoptosis of ovarian cancer cell lines. (a) qRT-PCR analysis of *ASBEL* expression in human ovarian cancerous and corresponding non-cancerous tissues. 1–5, serous adenocarcinoma; 6 and 7, endometrioid adenocarcinoma; 8 and 9, clear cell adenocarcinoma; 10, mucinous adenocarcinoma; 11, dysgerminoma. Prior to fold-change calculation, the values were normalized to the signal generated from *GAPDH* mRNA. (b) qRT-PCR analysis of *ASBEL* expression in JHOC5 cells infected with a lentivirus harbouring an shRNA targeting *ASBEL*. Error bars represent the s.d. (n = 3). (c) Viability of ovarian cancer cell lines infected with a lentivirus expressing an shRNA targeting *ASBEL* was assessed by MTT assays. *, P < 0.05. (d) Viability of ovarian cancer cell lines transfected with siRNA targeting *ASBEL* was assessed by CellTiter-Glo assays. *, P < 0.05. (e) Annexin assays were performed with JHOC5 cells that had been infected with a lentivirus expressing an shRNA targeting *ASBEL*. *, P < 0.05. (f) JHOC5 cells infected with a lentivirus expressing an shRNA targeting *ASBEL* were injected into nude mice. Sizes of tumors were measured once a week using calipers. Results are expressed as the mean \pm s.e.m. (1×10^5 , n = 6). *, P < 0.05.

gradients. Knockdown of *ASBEL* did not change the polysome distribution profiles (Supplementary Fig. S5, lower panel), indicating that *ASBEL* does not affect global translation. qRT-PCR analysis of RNA isolated from each fraction revealed that knockdown of *ASBEL* did not induce changes in the size of polysomes translating *ANA/BTG3* and *HPRT1* mRNAs. These results suggest that *ASBEL* does not affect the translation of *ANA/BTG3* mRNA. Thus, *ASBEL* may inhibit *ANA/BTG3* protein expression by forming *ASBEL-ANA/BTG3* RNA duplexes, which are retained in the nucleus (Fig. 5).

Discussion

In the present study, we have shown that *ASBEL*, a natural antisense transcript of the *ANA/BTG3* gene, negatively regulates the expression of *ANA/BTG3*. This is the first report showing the mechanism underlying the regulation of *ANA/BTG3* expression. Furthermore, we showed that *ASBEL* is required for proliferation and tumorigenicity of ovarian cancer. Thus, we speculate that downregulation of

ANA/BTG3 by *ASBEL* is critical for proliferation and tumorigenicity of ovarian cancer. This notion is supported by the results of our rescue experiments showing that knockdown of *ANA/BTG3* using shRNA rescues growth inhibition caused by *ASBEL* knockdown. These results are consistent with previous reports that *ANA/BTG3* plays a critical role in cell proliferation and is downregulated in prostate and lung cancers^{14–16,18,19}. It is possible that *ASBEL* is also involved in the tumorigenicity of cancers other than ovarian cancer, including prostate and lung cancers. Indeed, our preliminary results show that *ASBEL* is required for proliferation and tumorigenicity of colon cancer cells.

It has been reported that antisense transcripts regulate gene expression at various steps in the post-transcriptional processing of mRNAs². We showed that *ASBEL* hybridizes and generates *ASBEL-ANA/BTG3* RNA duplexes in vivo. It is well known that mRNA expression of several genes, including *p53*, β -secretase-1 (*BACE1*) and inducible nitric oxide synthase (*INOS*), is regulated by duplex




Figure 3 | ASBEL downregulates ANA/BTG3 protein, but not mRNA expression. (a) qRT-PCR analysis of *ASBEL* and *ANA/BTG3* expression in ovarian cancer cell lines transfected with siRNA targeting *ASBEL*. Prior to fold-change calculation, the values were normalized to the signal generated from *GAPDH* mRNA. (b) Cell lysates from ovarian cancer cell lines transfected with siRNA targeting *ASBEL* were subjected to immunoblotting analysis with antibodies against the indicated proteins. α -tubulin was used as a loading control. (c) (Left) qRT-PCR analysis of *ANA/BTG3* expression in JHOC5 cells transfected with either the sense or antisense *ASBEL* expression plasmid. (Right) Cell lysates were subjected to immunoblotting analysis with antibodies against the indicated proteins. α -tubulin was used as a loading control. (d) qRT-PCR analysis of *ASBEL* and *ANA/BTG3* expression in JHOC5 cells infected with a lentivirus expressing an shRNA targeting *ANA/BTG3*. (e) JHOC5 cells that had been infected with a lentivirus expressing shRNA targeting *ANA/BTG3* was transfected with siRNA targeting *ASBEL* and their viability was assessed. *, $P < 0.05$.

formation with their antisense transcript^{5,6,10}. However, *ASBEL* does not affect *ANA/BTG3* mRNA expression but rather regulates the levels of *ANA/BTG3* protein. Furthermore, our subcellular fractionation and RT-PCR analyses revealed that *ASBEL* forms duplexes with *ANA/BTG3* mRNA in the nucleus and suppresses its cytoplasmic transportation (Fig. 5). Although some ncRNAs such as the nuclear-retained ncRNA *MALAT1* are known to regulate alternative splicing²², our results showed that *ASBEL* does not affect splicing of *ANA/BTG3* mRNA. The mechanism by which *ASBEL* inhibits cytoplasmic transportation of *ASBEL-ANA/BTG3* RNA duplexes remains to be elucidated. Investigation of the normal function of *ASBEL* and regulation of its activity is also underway in our laboratories.

Methods

Cell culture. OVI5E, JHOC5, JHOC9, OV1063, and 2008 cells were cultured in RPMI1640 supplemented with 10% bovine serum. 293FT cells were cultured in DMEM supplemented with 10% bovine serum.

Antibodies. Anti-FLAG (F3165) antibody was obtained from Sigma. Anti-Lamin A/C (612162) antibody was obtained from BD Biosciences. Anti- α -tubulin (CP-06) antibody was from CALBIOCHEM. Anti-*ANA/BTG3* antibody was prepared as described previously¹⁷.

Strand-specific RT-PCR. RNA isolated using TRIreagent (BIOLINE) was treated with DNase I (TAKARA), and reverse transcribed using Superscript III (Invitrogen) in the presence of strand-specific primers (2 pmol) (Supplementary Table S1) or oligo(dT) (500 ng) at 55°C. PCR amplification was performed using the indicated primers.

Northern blot. Total RNA was isolated using TRIreagent (BIOLINE) and poly(A)⁺-enriched RNA was purified using Dynabeads Oligo (dT)₂₅ magnetic beads (Invitrogen). Poly(A)⁺-enriched RNA was boiled in formamide loading buffer, separated by gel electrophoresis with a 2% denaturing formaldehyde gel in 1 × MOPS buffer, transferred to Hybond N+ (Amersham) in 20 × SSC (3 M NaCl, 0.3 M Na₃-citrate). Membranes were cross-linked by ultraviolet irradiation and hybridized over-night at 60°C with ³²P-dCTP-labelled DNA probes in Hybridization Buffer (7% SDS, 0.5 M Sodium Phosphate, pH7.2, 1 mM EDTA). The membranes were washed with NB Wash Buffer A (1 × SSC, 0.1% SDS) for 10 min at 25°C and then twice with NB Wash Buffer B (2 × SSC, 0.5% SDS) for 20 min at 60°C. Signals were visualized on a phosphorimager (Typhoon FLA 7000, GE Healthcare). DNA probes were labelled with ³²P-dCTP using the Megaprime DNA Labelling System (GE Healthcare). Primers used for generating probes are shown in Supplementary Table S2 online.

qRT-PCR analysis. Total RNA was isolated using the Total RNA Isolation kit (MACHEREY-NAGEL) and treated with DNase I (TAKARA). One microgram RNA was reverse transcribed using PrimeScript RT Master Mix (TAKARA, RR036A). qRT-PCR analysis of cDNA was performed on a LightCycler 480 (Roche Applied Science) using Syber Green PCR mastermix (Applied Biosystems). Primers used for qRT-PCR are shown in Supplementary Table S3 online.

Patients and specimens. Tissue samples of eleven ovarian cancers were obtained from the Jikei University hospital, Tokyo. Informed consent was obtained from all patients. This study was approved by the Ethics Committee of the Jikei University and the University of Tokyo. Eleven ovarian cancer samples include 5 serous adenocarcinoma, 2 endometrioid adenocarcinoma, 2 clear cell adenocarcinoma, 1 mucinous adenocarcinoma, and 1 dysgerminoma.

Lentivirus production. Lentiviral vector (CS-Rfa-CG) harbouring an shRNA driven by the H1 promoter was transfected with the packaging vectors pCAG-HIV-gp and pCMV-VSV-G-RSV-Rev into 293FT cells using polyethylenimine 'MAX' (PEI, Polyscience, Inc. Cat. 24765). All plasmids were kindly provided by H. Miyoshi (RIKEN BioResource Center, Japan). Virus supernatants were purified by ultracentrifugation at 25,000 rpm for 90 min (SW28 rotor, Beckman). Infection efficiency was monitored by GFP expression as it is driven by the CMV promoter. The sequences of shRNAs are shown in Supplementary Table S4 online.

RNA interference. Stealth siRNA duplexes targeting *ANA/BTG3* were purchased from Invitrogen. siRNA duplexes targeting *ASBEL* were purchased from Exiqon. Cells were transfected with RNA duplexes using Lipofectamine RNAiMAX (Invitrogen). The sequences of siRNAs are shown in Supplementary Table S4 online. Validated Stealth negative control RNAi duplex with MED GC content #2 (Invitrogen) or siRNA negative control (Exiqon, S20C-0600) was used as a control.

Constructs and transfection. An oligonucleotide coding for an RNA hairpin that binds bacteriophage pp7 coat protein^{23,24} was cloned as an NheI-HindIII fragment in pcDNA3.1(+) (Invitrogen) [termed pcDNA3.1(+)-pp7-5']. FLAG tag and the nuclear localization signal from the SV40 large T-antigen was added to the 5' end of the pp7 coat protein cDNA [a gift from D. S. Peabody (University of New Mexico School of Medicine)] by PCR and cloned into pcDNA3.1(+). *ASBEL*, *ASBEL-Del-1* (1 to 926), *ASBEL-Del-2* (1 to 1178), *ASBEL-Del-3* (927 to 2312), *ASBEL-Del-4* (1179 to 2312) were amplified by PCR using corresponding specific primers and cloned into pcDNA3.1(+)-pp7-5'. A fragment containing the *ANA/BTG3* 5' UTR was amplified by PCR from the JHOC5 genome and was subcloned with the *ANA/BTG3* ORF into pcDNA3.1(+). Primers used for construction are shown in Supplementary Table S5 online. Plasmids were transfected into cells using polyethylenimine 'MAX' (PEI, Polyscience, Inc. Cat. 24765).

Immunoblotting. Cells (5×10^6) were lysed for 20 min with lysis buffer (0.5% Triton X-100, 100 mM NaCl, 50 mM Tris-HCl pH7.5, 2 mM EDTA, 50 mM sodium fluoride) containing protease inhibitors. After centrifugation at 23,100 × g for 20 min at 4°C, samples were resolved by SDS-PAGE and then transferred to PVDF membranes (Immobilon-P, Millipore) and analyzed by immunoblotting using HRP-conjugated secondary antibodies. Membranes were blocked with 5% skimmed milk in TBS plus Tween 20 at 4°C overnight before probing with antibodies. Visualization was performed using the Enhanced Chemiluminescence Plus Western Blotting Detection System (GE Healthcare) and LAS-4000EPUVmini Luminescent Image Analyzer (GE Healthcare).

Apoptosis. Phosphatidylserine (PS) exposure at the cell surface was detected using the Annexin V-Biotin Apoptosis Detection Kit (MBL) and Streptavidin-APC conjugates (S888, Invitrogen) according to the manufacturer's instruction.

MTT assay. One week after lentivirus infection, cells were treated with C3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) (Calbiochem) for 4 h. Cell viability was determined by measuring the absorbance at 570 nm using a




Figure 4 | ASBEL forms duplexes with ANA/BTG3 mRNA and prevents its nuclear-cytoplasmic transportation. (a) Schematic representation of the genomic organization of the region containing ASBEL and ANA/BTG3 and the ASBEL mutant constructs used in RIP assays. (b, c) RIP assay. Lysates prepared from JHOC5 cells transfected with the wild type, antisense (*Antisense-ASBEL*) or mutant *pp7-ASBEL* (ASBEL fused to a pp7 coat protein-binding sequence), ANA/BTG3 mRNA and FLAG-tagged pp7 coat protein expression constructs were subjected to immunoprecipitation with anti-FLAG antibody followed by RT-PCR analysis to detect ANA/BTG3 mRNA. Four mutants shown in (a) were used in (c). The apparent immunoprecipitation efficiency for a specific RNA was calculated by dividing the amount of RT-PCR product obtained in the immunoprecipitated sample by the amount obtained from the input RNA. *HPRT1* was used as a negative control. (d) Subcellular distribution of ANA/BTG3 mRNA and ANA/BTG3 protein. JHOC5 cells transfected with siRNA targeting ASBEL or control siRNA were subjected to subcellular fractionation. (Left) The amounts of the indicated RNAs in each fraction were evaluated by RT-PCR analysis. *U1* was used as a loading control. (Right) The cytoplasmic fraction was subjected to immunoblotting analysis with antibodies against the indicated proteins. α -tubulin was used as a loading control.




Figure 5 | The ncRNA ASBEL is required for tumorigenicity of ovarian cancer. ASBEL forms duplexes with ANA/BTG3 mRNA in the nucleus and suppresses its nuclear-cytoplasmic transportation. ASBEL-mediated inhibition of ANA/BTG3 protein expression may be important for the tumorigenicity of ovarian cancer.



Mithras LB 940 (Berthold). The absorbance values of formazan were calculated as a percentage of the control wells.

CellTiter-Glo. Cell viability was determined indirectly by measuring the intracellular levels of ATP using the CellTiter-Glo Luminescent Cell Viability Assay kit (Promega). Luminescence was measured on a Mithras LB 940 (Berthold).

Subcutaneous xenograft. JHOC5 cells infected with a lentivirus expressing an shRNA targeting *ASBEL* were injected stereotactically into 6-week-old nude mice (BALB/cA)cl-*nu/nu*, CLEA Japan). All animal experimental protocols were performed in accordance with the guidelines of the Animal Ethics Committee of the University of Tokyo.

RIP assay. Cells growing in 6-well dishes were lysed in 0.5 ml of 0.5% Lysis buffer (50 mM HEPES pH7.5, 150 mM KCl, 0.5% NP40, 2 mM EDTA, 1 mM NaF) containing protease inhibitors and RNase Inhibitor (Promega), and centrifuged at 13,000 r.p.m. for 10 min. The supernatant were incubated with anti-FLAG antibody for 3 h at 4°C with gentle rotation. Thirty microliters of Protein G Dynabeads (Invitrogen) were added and then incubated for 1 h at 4°C with gentle rotation. The beads were washed thrice with Wash buffer (50 mM HEPES pH7.5, 150 mM KCl, 0.05% NP40) containing RNase Inhibitor (Promega) and then twice with PBS containing RNase Inhibitor (Promega). RNA was extracted using the Total RNA Isolation kit (MACHEREY-NAGEL) and qRT-PCR was performed as described above. Primers for qRT-PCR are shown in Supplementary Table S3 online.

Subcellular fractionation. Cells were washed and harvested in PBS. The pellet was resuspended in 1 packed cell volume of Hypotonic Buffer (10 mM HEPES pH 7.5, 10 mM KCl, 1.5 mM MgCl₂). After incubation on ice for 10 min, cells were disrupted by 10 passages through a 25-gauge needle. Cells were centrifuged for 10 min at 1,000 g at 4°C and the supernatant containing the cytoplasmic fraction was collected by further centrifugation at 17,000 g for 15 min. The remaining pellet was washed twice with Hypotonic Buffer, resuspended in Hypertonic Buffer (20 mM HEPES pH 7.5, 420 mM KCl, 1.5 mM MgCl₂, 0.5% NP40) and incubated at 4°C for 30 min with gentle rotation. The supernatant containing the nuclear fraction was collected by centrifugation at 18,000 g for 15 min.

Polysome preparation. The JHOC5 cytoplasmic fraction in hypotonic buffer (10 mM HEPES pH 7.5, 10 mM KCl, 1.5 mM MgCl₂, 150 µg/mL cycloheximide) was layered onto a 10mL linear sucrose gradient (10%-55% sucrose, 50 mM Tris-HCl pH7.5, 75 mM KCl, 1.5 mM MgCl₂, 0.5 mM DTT) containing protease inhibitors and RNase Inhibitor (Promega), and centrifuged in a SW40Ti rotor (Beckman) for 15 h at 25,000 rpm at 4°C. Fractions were collected with a Piston Gradient Fractionator (Biocomp). RNA was extracted using the Total RNA Isolation kit (MACHEREY-NAGEL).

- Katayama, S. *et al.* Antisense transcription in the mammalian transcriptome. *Science* **309**, 1564–1566 (2005).
- Faghihi, M. A. & Wahlestedt, C. Regulatory roles of natural antisense transcripts. *Nat. Rev. Mol. Cell Biol.* **10**, 637–643 (2009).
- Hastings, M. L., Milcarek, C., Martincic, K., Peterson, M. L. & Munroe, S. H. Expression of the thyroid hormone receptor gene, *erbAalpha*, in B lymphocytes: alternative mRNA processing is independent of differentiation but correlates with antisense RNA levels. *Nucleic Acids Res.* **25**, 4296–4300 (1997).
- Peters, N. T., Rohrbach, J. A., Zalewski, B. A., Byrket, C. M. & Vaughn, J. C. RNA editing and regulation of *Drosophila* 4f-rnp expression by *sas-10* antisense readthrough mRNA transcripts. *RNA* **9**, 698–710 (2003).
- Faghihi, M. A. *et al.* Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of beta-secretase. *Nat. Med.* **14**, 723–730 (2008).
- Matsui, K. *et al.* Natural antisense transcript stabilizes inducible nitric oxide synthase messenger RNA in rat hepatocytes. *Hepatology* **47**, 686–697 (2008).
- Uchida, T. *et al.* Prolonged hypoxia differentially regulates hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression in lung epithelial cells: implication of natural antisense HIF-1alpha. *J. Biol. Chem.* **279**, 14871–14878 (2004).
- Hatzoglou, A. *et al.* Natural antisense RNA inhibits the expression of BCMA, a tumour necrosis factor receptor homologue. *BMC Mol. Biol.* **3**, 4 (2002).
- Ebralidze, A. K. *et al.* PU.1 expression is modulated by the balance of functional sense and antisense RNAs regulated by a shared cis-regulatory element. *Genes Dev.* **22**, 2085–2092 (2008).

- Mahmoudi, S. *et al.* Wrap53, a natural p53 antisense transcript required for p53 induction upon DNA damage. *Mol. Cell* **33**, 462–471 (2009).
- Tufarelli, C. *et al.* Transcription of antisense RNA leading to gene silencing and methylation as a novel cause of human genetic disease. *Nat. Genet.* **34**, 157–165 (2003).
- Yu, W. *et al.* Epigenetic silencing of tumour suppressor gene p15 by its antisense RNA. *Nature* **451**, 202–206 (2008).
- Morris, K. V., Santoso, S., Turner, A. M., Pastori, C. & Hawkins, P. G. Bidirectional transcription directs both transcriptional gene activation and suppression in human cells. *PLoS Genet.* **4**, e1000258 (2008).
- Winkler, G. S. The mammalian anti-proliferative BTG/Tob protein family. *J. Cell. Phys.* **222**, 66–72 (2010).
- Lin, T. Y. *et al.* Loss of the candidate tumor suppressor BTG3 triggers acute cellular senescence via the ERK-JMJD3-p16(INK4a) signaling axis. *Oncogene* **31**, 3287–3297 (2012).
- Ou, Y. H. *et al.* The candidate tumor suppressor BTG3 is a transcriptional target of p53 that inhibits E2F1. *EMBO J.* **26**, 3968–3980 (2007).
- Yoshida, Y., Hosoda, E., Nakamura, T. & Yamamoto, T. Association of ANA, a member of the antiproliferative Tob family proteins, with a C/EBP component of the CCR4 transcriptional regulatory complex. *Jan. J. Cancer Res.* **92**, 592–596 (2001).
- Majid, S. *et al.* BTG3 tumor suppressor gene promoter demethylation, histone modification and cell cycle arrest by genistein in renal cancer. *Carcinogenesis* **30**, 662–670 (2009).
- Yoneda, M. *et al.* Deficiency of antiproliferative family protein Ana correlates with development of lung adenocarcinoma. *Cancer Sci.* **100**, 225–232 (2009).
- Mahmoudi, S. *et al.* Wrap53, a natural p53 antisense transcript required for p53 induction upon DNA damage. *Mol. Cell* **33**, 462–471 (2009).
- Dalosso, A. R. *et al.* Alternately spliced WT1 antisense transcripts interact with WT1 sense RNA and show epigenetic and splicing defects in cancer. *RNA* **13**, 2287–2299 (2007).
- Tripathi, V. *et al.* The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. *Mol. Cell* **39**, 925–938 (2010).
- Lim, F. & Peabody, D. S. RNA recognition site of PP7 coat protein. *Nucleic Acids Res.* **30**, 4138–4144 (2002).
- Lim, F., Downey, T. P. & Peabody, D. S. Translational repression and specific RNA binding by the coat protein of the Pseudomonas phage PP7. *J. Biol. Chem.* **276**, 22507–22513 (2001).

Acknowledgements

This work was supported by Research Program of Innovative Cell Biology by Innovative Technology (Integrated Systems Analysis of Cellular Oncogenic Signaling Networks), Grants-in-Aid for Scientific Research on Innovative Areas (Integrative Research on Cancer Microenvironment Network), Project for Development of Innovative Research on Cancer Therapeutics, Takeda Science Foundation and in part by Global COE Program (Integrative Life Science Based on the Study of Biosignaling Mechanisms), MEXT, Japan.

Author contributions

S.Y., K.T., A.O. and T.A. conceived the project and designed the experiments. S.Y. and K.T. performed most of the experiments. H.S., E.N., Y.T., M.K., K.O. generated some expression constructs and performed RT-PCR analyses. T.Y. prepared anti-ANA/BTG3 antibody. S.Y. and A.O. prepared ovarian cancer specimens. S.Y., K.T., A.O. and T.A. wrote the manuscript.

Additional information

Supplementary information accompanies this paper at <http://www.nature.com/scientificreports>

Competing financial interests: The authors declare no competing financial interests.

License: This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-nd/3.0/>

How to cite this article: Yanagida, S. *et al.* *ASBEL*, an ANA/BTG3 antisense transcript required for tumorigenicity of ovarian carcinoma. *Sci. Rep.* **3**, 1305; DOI:10.1038/srep01305 (2013).